119th Congress · introduced in the House · Feb 24, 2025
New Era of Preventing End-Stage Kidney Disease Act
Official title from Congress.gov
Latest action (Feb 24, 2025): Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
View on Congress.govPolicy area: Health
Congressional Research Service summary, version: Introduced in House (Feb 24, 2025)
New Era of Preventing End-Stage Kidney Disease Act
This bill establishes regional centers of excellence, postgraduate fellowships, and training for health professionals relating to the diagnosis and treatment of rare kidney disease. It also requires the Department of Health and Human Services (HHS) to conduct various studies on rare kidney disease.
Specifically, it authorizes the National Institute of Diabetes and Digestive and Kidney Diseases to award funding to public and private nonprofit entities for establishing regional centers of excellence that will increase public awareness, conduct research, and develop resources for diagnosing and treating rare kidney diseases. A center may receive such funding for up to five years, unless extended by the institute.
The bill also requires health professions schools receiving a grant from the Health Resources and Services Administration (HRSA) Centers of Excellence program to award fellowships for training on preventing, diagnosing, and treating rare kidney disease in disproportionately impacted populations.
Also, the bill expands the priorities of HRSA’s Primary Care Training and Enhancement program to include training for health care workers to care for individuals with kidney disease.
Additionally, HHS must conduct several studies and report to Congress on topics such as treating rare kidney disease in disproportionately affected populations, eliminating the need for dialysis or kidney transplants, and increasing public awareness of rare kidney disease.
Includes amendment, cloture, and procedural votes. Each is labeled with its exact question; only a passage question is a vote to pass the bill.
No recorded roll calls on this bill in coverage.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Introduced in House
Introduced in House
Actions from Congress.gov, newest first.
Congressional oversight · Digestive and metabolic diseases · Genetics · Government studies and investigations · Health care coverage and access · Health programs administration and funding · Health promotion and preventive care · Medical education · Medical research · Medical tests and diagnostic methods · Research administration and funding
LD-2 reports whose issue descriptions explicitly cite this bill (bill type and number validated against Congress.gov records). A citation does not establish the client's position or any contact with a member.
Loading lobbying reportsCoverage: reports for 2025 onward, posted Jan 1, 2025 through Oct 23, 2026.
45 citations; showing the 25 most recently posted.
TRAVERE THERAPEUTICS · lobbying firm or registrant: ALSTON & BIRD LLP
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
$80,000
Paid to lobbying firm
…rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. H.R.10571, Surge to Save Newborns Act. H.R.1518, New Era of Preventing End-Stage Kidney Disease Act. Support of reauthorization of priority review voucher program. Pub. L. No. 119-21, One Big Beautiful Bill…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
TRAVERE THERAPEUTICS · lobbying firm or registrant: ALSTON & BIRD LLP
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Medicare/Medicaid
$80,000
Paid to lobbying firm
H.R.1518, New Era of Preventing End-Stage Kidney Disease Act. Pub. L. No. 119-21, One Big Beautiful Bill Act, provisions regarding orphan drugs, Medicare and Medicaid.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICAN KIDNEY FUND · lobbying firm or registrant: AMERICAN KIDNEY FUND
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
$220,000
Spent on own lobbying
…Donor Protection Act: H.R. 4582, H.R 4583, S. 1552 Appropriations-NIH, NIDDK, Kidney Research The New Era for Preventing End-Stage Kidney Disease Act of 2025: H.R. 1518. Restore Protections for Dialysis Patients Act: H.R. 2199; S. 1173. Permanent OPTN Fee Authority Act: H.R.5259; S. 2751. Kidney Care Access Protection Act: S.2…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
VERTEX PHARMACEUTICALS · lobbying firm or registrant: TIBER CREEK GROUP
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
$60,000
Paid to lobbying firm
Issues related to drug pricing; Issues related to H.R. 1227/S. 475 - Alternatives to PAIN Act; Issues related to H.R. 1518 - New Era of Preventing End-Stage Kidney Disease Act.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
TRAVERE THERAPEUTICS · lobbying firm or registrant: TRAVERE THERAPEUTICS
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
$100,000
Spent on own lobbying
…tion regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. HR 1518, the New Era of Preventing End-Stage Kidney Disease Act; end-stage renal disease policy and rare kidney disease; HR 10571, the Surge to Save Newborns Act
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
VERTEX PHARMACEUTICALS INCORPORATED · lobbying firm or registrant: VERTEX PHARMACEUTICALS INCORPORATED
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 19, 2026 · issue area: Health Issues
$1,100,000
Spent on own lobbying
…ograms; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1 and H.R. 1518 - New Era of Preventing End-Stage Kidney Disease; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
OTSUKA AMERICA PHARMACEUTICAL, INC. · lobbying firm or registrant: OTSUKA AMERICA PHARMACEUTICAL, INC.
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 15, 2026 · issue area: Health Issues
$310,000
Spent on own lobbying
…care and mental health equity. PBM reform. Issues related to rare nephrology/kidney diseases, 340B reform, psychedelics treatments for PTSD and mental health. H.R. 1518, the New Era of Preventing End-Stage Kidney Disease Act. Issues related to drug pricing, foreign reference pricing, biomedical research, and pharmaceutical sup…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
TRAVERE THERAPEUTICS · lobbying firm or registrant: ALSTON & BIRD LLP
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Health Issues
$70,000
Paid to lobbying firm
…re disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. Legislation regarding newborn screening. H.R.1518, New Era of Preventing End-Stage Kidney Disease Act. Support of reauthorization of priority review voucher program. Pub. L. No. 119-21, One Big Beautiful Bill…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
TRAVERE THERAPEUTICS · lobbying firm or registrant: ALSTON & BIRD LLP
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Medicare/Medicaid
$70,000
Paid to lobbying firm
H.R.1518, New Era of Preventing End-Stage Kidney Disease Act. Pub. L. No. 119-21, One Big Beautiful Bill Act, provisions regarding orphan drugs, Medicare and Medicaid.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICAN KIDNEY FUND · lobbying firm or registrant: AMERICAN KIDNEY FUND
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Health Issues
$240,000
Spent on own lobbying
…Donor Protection Act: H.R. 4582, H.R 4583, S. 1552 Appropriations-NIH, NIDDK, Kidney Research The New Era for Preventing End-Stage Kidney Disease Act of 2025: H.R. 1518. Restore Protections for Dialysis Patients Act: H.R. 2199; S. 1173. Permanent OPTN Fee Authority Act: H.R.5259; S. 2751. Kidney Care Access Protection Act: S.2…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
TRAVERE THERAPEUTICS · lobbying firm or registrant: TRAVERE THERAPEUTICS
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Health Issues
$140,000
Spent on own lobbying
…tion regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. HR 1518, the New Era of Preventing End-Stage Kidney Disease Act; end-stage renal disease policy and rare kidney disease
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
VERTEX PHARMACEUTICALS · lobbying firm or registrant: TIBER CREEK GROUP
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 18, 2026 · issue area: Health Issues
$60,000
Paid to lobbying firm
Issues related to drug pricing; Issues related to H.R. 1227/S. 475 - Alternatives to PAIN Act; Issues related to H.R. 1518 - New Era of Preventing End-Stage Kidney Disease Act.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICAN SOCIETY OF NEPHROLOGY · lobbying firm or registrant: AMERICAN SOCIETY OF NEPHROLOGY
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 16, 2026 · issue area: Health Issues
$60,000
Spent on own lobbying
…05/S 4070) -H-1Bs for Physicians and Healthcare Workforce Act (HR 7961) Living Organ Volunteer Engagement (LOVE) Act (HR 7581) -New Era of Preventing ESRD Act (HR 1518) -PKD Cures Act (HR 9169)
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
VERTEX PHARMACEUTICALS INCORPORATED · lobbying firm or registrant: VERTEX PHARMACEUTICALS INCORPORATED
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 16, 2026 · issue area: Health Issues
$1,200,000
Spent on own lobbying
…ograms; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1 and H.R. 1518 - New Era of Preventing End-Stage Kidney Disease; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
OTSUKA AMERICA PHARMACEUTICAL, INC. · lobbying firm or registrant: OTSUKA AMERICA PHARMACEUTICAL, INC.
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 16, 2026 · issue area: Health Issues
$1,240,000
Spent on own lobbying
…care and mental health equity. PBM reform. Issues related to rare nephrology/kidney diseases, 340B reform, psychedelics treatments for PTSD and mental health. H.R. 1518, the New Era of Preventing End-Stage Kidney Disease Act. Issues related to drug pricing, foreign reference pricing, biomedical research, and pharmaceutical sup…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
NATIONAL KIDNEY FOUNDATION · lobbying firm or registrant: NATIONAL KIDNEY FOUNDATION
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 9, 2026 · issue area: Health Issues
$80,000
Spent on own lobbying
…ion of the Advancing American Kidney Health Initiative. Support for telemedicine and telehealth access. The New Era of Preventing End-Stage Kidney Disease Act (H.R. 1518). Support for access to affordable, accessible health care, including Affordable Care Act enhanced premium tax credits.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
TRAVERE THERAPEUTICS · lobbying firm or registrant: ALSTON & BIRD LLP
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 21, 2026 · issue area: Health Issues
$80,000
Paid to lobbying firm
…re disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. Legislation regarding newborn screening. H.R.1518, New Era of Preventing End-Stage Kidney Disease Act. Support of reauthorization of priority review voucher program. Pub. L. No. 119-21, One Big Beautiful Bill…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
TRAVERE THERAPEUTICS · lobbying firm or registrant: ALSTON & BIRD LLP
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 21, 2026 · issue area: Medicare/Medicaid
$80,000
Paid to lobbying firm
H.R.1518, New Era of Preventing End-Stage Kidney Disease Act. Pub. L. No. 119-21, One Big Beautiful Bill Act, provisions regarding orphan drugs, Medicare and Medicaid.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICAN KIDNEY FUND · lobbying firm or registrant: AMERICAN KIDNEY FUND
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 20, 2026 · issue area: Health Issues
$230,000
Spent on own lobbying
…Donor Protection Act: H.R. 4582; H.R 4583; S. 1552 Appropriations-NIH, NIDDK, Kidney Research The New Era for Preventing End-Stage Kidney Disease Act of 2025: H.R. 1518. Restore Protections for Dialysis Patients Act: H.R. 2199; S. 1173. Enhanced Advance Premium Tax Credits (eAPTCs) Permanent OPTN Fee Authority Act: H.R.5259; S…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
TRAVERE THERAPEUTICS · lobbying firm or registrant: TRAVERE THERAPEUTICS
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 20, 2026 · issue area: Health Issues
$200,000
Spent on own lobbying
…tion regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. HR 1518, the New Era of Preventing End-Stage Kidney Disease Act; end-stage renal disease policy and rare kidney disease
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
VERTEX PHARMACEUTICALS · lobbying firm or registrant: TIBER CREEK GROUP
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 19, 2026 · issue area: Health Issues
$60,000
Paid to lobbying firm
Issues related to drug pricing; Issues related to H.R. 1227/S. 475 - Alternatives to PAIN Act; Issues related to H.R. 1518 - New Era of Preventing End-Stage Kidney Disease Act.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
VERTEX PHARMACEUTICALS INCORPORATED · lobbying firm or registrant: VERTEX PHARMACEUTICALS INCORPORATED
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 17, 2026 · issue area: Health Issues
$1,140,000
Spent on own lobbying
…ograms; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1 and H.R. 1518 - New Era of Preventing End-Stage Kidney Disease; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
OTSUKA AMERICA PHARMACEUTICAL, INC. · lobbying firm or registrant: OTSUKA AMERICA PHARMACEUTICAL, INC.
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 17, 2026 · issue area: Health Issues
$210,000
Spent on own lobbying
…care and mental health equity. PBM reform. Issues related to rare nephrology/kidney diseases, 340B reform, psychedelics treatments for PTSD and mental health. H.R. 1518, the New Era of Preventing End-Stage Kidney Disease Act. Issues related to drug pricing, foreign reference pricing, biomedical research, and pharmaceutical sup…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
NATIONAL KIDNEY FOUNDATION · lobbying firm or registrant: NATIONAL KIDNEY FOUNDATION
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 17, 2026 · issue area: Health Issues
$100,000
Spent on own lobbying
…ion of the Advancing American Kidney Health Initiative. Support for telemedicine and telehealth access. The New Era of Preventing End-Stage Kidney Disease Act (H.R. 1518). Activities in support of access to affordable, accessible health care, including Affordable Care Act enhanced premium tax credits.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
TRAVERE THERAPEUTICS · lobbying firm or registrant: ALSTON & BIRD LLP
2025 Q1 report (Jan 1, 2025 – Mar 31, 2025) · amended · posted Mar 3, 2026 · issue area: Health Issues
$60,000
Paid to lobbying firm
…re disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. Legislation regarding newborn screening. H.R.1518, New Era of Preventing End-Stage Kidney Disease Act. Policies regarding copay accumulators and impact on rare disease patients. Support of reauthorization of p…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing